SUPRIYA news

• 07-Nov-2026 23:05:48

  SUPRIYA LIFESCIENCE Q2 FY27 CONCALL: MAINTAINS ₹1,000 CR FY27 REVENUE GUIDANCE, CUTS EBITDA MARGIN OUTLOOK TO 23–25% FROM 32–35%; TARGETS 20%+ ANNUAL GROWTH OVER 3–4 YEARS, AMBARNATH ₹450–500 CR REVENUE POTENTIAL & MAJOR CDMO CONTRACT

  SUPRIYA LIFESCIENCE Q2 FY27 CONCALL: MAINTAINS ₹1,000 CR FY27 REVENUE GUIDANCE, CUTS EBITDA MARGIN OUTLOOK TO 23–25% FROM 32–35%; TARGETS 20%+ ANNUAL GROWTH OV…

• 06-Nov-2026 12:52:05

  SUPRIYA Q2 FY27 ; STANDALONE

  NET PROFIT DOWN 42.00% AT ₹29.25 CR (YOY), UP 21.66% (QOQ) REVENUE UP 3.23% AT ₹206.30 CR (YOY), UP 8.72% (QOQ) EBITDA DOWN 37.50% AT ₹45.40 CR (YOY), DOWN 4.3…

• 06-Nov-2026 12:51:32

  SUPRIYA LIFESCIENCE Q2 FY27 ; STANDALONE

  NET PROFIT DOWN 42% AT ₹29 CR (YOY), UP 22% (QOQ) REVENUE UP 3% AT ₹206 CR (YOY), UP 9% (QOQ) EBITDA DOWN 38% AT ₹45 CR (YOY), DOWN 4% (QOQ) MARGINS AT 22.0% V…

• 29-Jun-2026 16:18:16

  SUPRIYA LIFESCIENCE : DISCLOSES NO ENCUMBRANCE OF SHARES

  • Promoter and members of the Promoter Group have not made any encumbrance of shares, directly or indirectly, during the Financial Year ended March 31, 2026. •…

← Back to feed